<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A subset of patients (50%) with <z:e sem="disease" ids="C0948264" disease_type="Disease or Syndrome" abbrv="">neuroborreliosis</z:e> (<z:e sem="disease" ids="C0024198" disease_type="Disease or Syndrome" abbrv="">Lyme disease</z:e>) showed IgG reactivity to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> in solid phase ELISA </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, a subset of patients with <z:e sem="disease" ids="C0948264" disease_type="Disease or Syndrome" abbrv="">neuroborreliosis</z:e> (29%) and <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> (59%) had IgM reactivity to <z:chebi fb="0" ids="28892">gangliosides</z:chebi> with a <z:chebi fb="125" ids="28260">Gal</z:chebi>(beta 1-3) GalNac terminal sequence (GM1, GD1b, and asialo GM1) </plain></SENT>
<SENT sid="2" pm="."><plain>Anti-<z:chebi fb="0" ids="28892">ganglioside</z:chebi> IgM antibodies were significantly more frequent in these two groups of patients compared to patients with cutaneous and articular <z:e sem="disease" ids="C0024198" disease_type="Disease or Syndrome" abbrv="">Lyme disease</z:e>, <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e>, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="3" pm="."><plain>Correlative evidence and adsorption experiments indicated that antibodies to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> had separate specificities from those directed against the <z:chebi fb="0" ids="28892">gangliosides</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>IgM antibodies to <z:chebi fb="125" ids="28260">Gal</z:chebi>(beta 1-3) GalNac <z:chebi fb="0" ids="28892">gangliosides</z:chebi> appeared to have similar specificities since these were positively correlated and inhibitable by cross adsorption assays </plain></SENT>
<SENT sid="5" pm="."><plain>Given the clinical associations of patients with <z:e sem="disease" ids="C0948264" disease_type="Disease or Syndrome" abbrv="">neuroborreliosis</z:e> and <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> with IgM reactivity to <z:chebi fb="0" ids="28892">gangliosides</z:chebi> sharing the <z:chebi fb="125" ids="28260">Gal</z:chebi>(beta 1-3) GalNac terminus, we suggest that these antibodies could represent a response to injury in <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological disease</z:e> or a cross reactive event caused by spirochetes </plain></SENT>
</text></document>